The past few years may seem like the best of times for Moderna (NASDAQ: MRNA). The company launched its very first product: the coronavirus vaccine. And thanks to that product, Moderna brought in billions of dollars in revenue and profit. The vaccine also brought Moderna's messenger RNA technology to the forefront.

Moderna saw its share performance take off too. And that helped the company's market value soar more than 800% from pre-pandemic days to $64 billion today.

In recent times, Moderna's momentum has slowed. Investors have worried about potential declines in vaccine sales in a post-pandemic world. But Moderna's good times may be far from over. Let's check out where this company will be in five years.

Continue reading

Source Fool.com